PTEN-mutated breast cancers may exhibit altered signalling pathways, impacting responsiveness to targeted therapies, but other therapies targeting molecular pathways, such as PI3K inhibitors, represent an area of active research [30,31]. This evidence concerns the gene PTEN and breast carcinoma.